Fulvestrant Treatment Is Associated With Cholesterol Plasma Level Reduction in Hormone Receptor-Positive Metastatic Breast Cancer Patients

Cancer Biology and Therapy - United States
doi 10.4161/cbt.8.15.8959
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Phase II Trial of Fulvestrant With Metronomic Capecitabine for Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2014English

A Randomized Trial of Combination Anastrozole Plus Gefitinib and of Combination Fulvestrant Plus Gefitinib in the Treatment of Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer

Breast Cancer Research and Treatment
Cancer ResearchOncology
2012English

Emerging Data and Future Directions for CDK4/6 Inhibitor Treatment of Patients With Hormone Receptor Positive HER2-non-amplified Metastatic Breast Cancer

Asia-Pacific Journal of Clinical Oncology
MedicineOncology
2018English

Phase 1b Study of Orteronel in Postmenopausal Women With Hormone-Receptor Positive (HR+) Metastatic Breast Cancer

Investigational New Drugs
OncologyPharmacology
2016English

Fulvestrant: A Further Treatment Option for Patients With Metastatic Uterine Cancer?

Oncology Research and Treatment
Cancer ResearchOncologyHematology
2006English

Predictors of Prolonged Benefit From Palbociclib Plus Fulvestrant in Women With Endocrine-Resistant Hormone Receptor–positive/Human Epidermal Growth Factor Receptor 2–negative Metastatic Breast Cancer in PALOMA-3

European Journal of Cancer
Cancer ResearchOncology
2018English

Cost Effectiveness of Fulvestrant 500 Mg in Endocrine Therapy-Naïve Women With Hormone Receptor-Positive Advanced Breast Cancer in the UK

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Aberrations in Translational Regulation Are Associated With Poor Prognosis in Hormone Receptor-Positive Breast Cancer

Breast Cancer Research
Cancer ResearchOncology
2012English

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Geburtshilfe und Frauenheilkunde
GynecologyMidwiferyMaternityObstetrics
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy